- Report
- February 2026
- 250 Pages
Global
From €4163EUR$4,490USD£3,482GBP
- Report
- November 2026
- 388 Pages
Global
From €6485EUR$6,995USD£5,425GBP
- Report
- September 2026
- 310 Pages
Global
From €3871EUR$4,175USD£3,238GBP
- Report
- December 2025
- 150 Pages
Global
From €5516EUR$5,950USD£4,614GBP
- Report
- November 2026
- 181 Pages
Global
From €5424EUR$5,850USD£4,537GBP
- Report
- November 2026
- 482 Pages
Global
From €5424EUR$5,850USD£4,537GBP
- Report
- November 2026
- 193 Pages
Global
From €5424EUR$5,850USD£4,537GBP
- Report
- February 2026
- 250 Pages
Global
From €4163EUR$4,490USD£3,482GBP
- Report
- July 2026
- 276 Pages
Global
From €7408EUR$7,990USD£6,196GBP
- Report
- April 2026
- 280 Pages
Global
From €4636EUR$5,000USD£3,878GBP
- Report
- August 2026
- 190 Pages
Global
From €4404EUR$4,750USD£3,684GBP
- Report
- October 2026
- 308 Pages
Global
From €3500EUR$4,044USD£3,030GBP
- Report
- February 2026
- 133 Pages
Global
From €3500EUR$4,044USD£3,030GBP
- Report
- June 2026
- 150 Pages
Global
From €4497EUR$4,850USD£3,761GBP
- Report
- September 2026
United States
From €4449EUR$4,799USD£3,722GBP
- Report
- September 2026
- 310 Pages
Asia Pacific
From €3871EUR$4,175USD£3,238GBP
- Report
- May 2026
- 95 Pages
North America
From €3013EUR$3,250USD£2,520GBP
- Report
- March 2026
- 281 Pages
United States
From €4497EUR$4,850USD£3,761GBP
- Report
- November 2024
- 716 Pages
Global
From €4449EUR$4,799USD£3,722GBP
- Report
- October 2023
- 273 Pages
Global
From €4589EUR$4,950USD£3,839GBP

Kadcyla is an oncology drug used to treat certain types of breast cancer. It is a targeted therapy that works by blocking the HER2 protein, which is found in some types of breast cancer cells. Kadcyla is administered intravenously and is used in combination with other treatments such as chemotherapy and radiation. It is approved for use in the United States, Europe, and other countries.
Kadcyla is a relatively new drug and is still in the early stages of development. It is being studied in clinical trials for its potential to treat other types of cancer, such as ovarian and lung cancer. The drug is also being studied for its potential to reduce the risk of recurrence in patients who have already been treated for breast cancer.
The Kadcyla market is highly competitive, with several major pharmaceutical companies competing for market share. Companies such as Roche, Novartis, and Pfizer are all involved in the development and marketing of Kadcyla. Other companies such as Merck, AstraZeneca, and Eli Lilly are also involved in the development and marketing of the drug. Show Less Read more